華仁藥業(300110.SZ):碳酸氫鈉林格注射液及硫酸特布他林注射液擬中選集採
格隆匯12月13日丨華仁藥業(300110.SZ)公佈,公司及全資子公司安徽恒星製藥有限公司近期積極參加了國家組織藥品聯合採購辦公室組織的第十批全國藥品集中採購的投標工作。根據聯採辦近日發佈的全國藥品集中採購(採購文件編號:GY-YD2024-2)擬中選結果,公司產品碳酸氫鈉林格注射液及全資子公司安徽恒星製藥有限公司產品硫酸特布他林注射液擬中選本次集中採購。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.